Paraben-free fexofenadine formulation
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- オペラ ヘルスケア グループ ソシエテ パル アクシオン サンプリフィエ
- Filing Date
- 2023-06-19
- Publication Date
- 2026-06-19
AI Technical Summary
Existing fexofenadine formulations contain parabens, which raise safety concerns, and there is a need for a bioequivalent, paraben-free formulation that maintains stability and solubility while masking the bitter taste.
A paraben-free fexofenadine formulation with a pH range of 5.8 to 7.0, using fexofenadine zwitterionic dihydrate Form I, a wetting agent, suspending agent, sweetener system, preservative system, and buffer system, including potassium sorbate, domiphen bromide, cetylpyridinium chloride, or sodium benzoate, and a flavoring agent, to maintain stability and solubility.
The formulation achieves bioequivalence to current fexofenadine suspensions without parabens, ensuring stability and solubility, while masking the bitter taste and maintaining safety.
Smart Images

Figure 2024153354000001 
Figure 2024153354000002 
Figure 2024153354000003